1691249-45-2
- Product Name：Zanubrutinib
- Molecular Formula：C27H29N5O3
- Purity：99%
- Molecular Weight：471.55
Product Details:
CasNo： 1691249-45-2
Molecular Formula： C27H29N5O3
Purity： 99%
Synonyms: The BTK inhibitor; Zanubrutinib(BGB-3111); BGB-3111; ZANUBRUTINIB; BGB3111; BGB3111; (S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide; Pyrazolo[1,5-a]pyrimidine-3-carboxamide,4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-,(7S)-
Boiling point: 713.4±60.0 °C
Density: 1.33±0.1 g/cm3
Solubility: DMSO: 99.67 (Max Conc. mg/mL); 211.36 (Max Conc. mM)
DMF: 10.0 (Max Conc. mg/mL); 21.21(Max Conc. mM)
DMF: PBS (pH 7.2) (1:5): 0.16 (Max Conc. mg/mL); 0.34 (Max Conc. mM)
Ethanol: 33.33 (Max Conc. mg/mL); 70.68 (Max Conc. mM)
Pka: 15.35±0.40
Form: Solid
Color: White to off-white
Description:
Zanubrutinib, a second-generation BTK inhibitor, has been approved by the FDA (in 2019) for treating chronic lymphocytic leukemia (CLL) and certain other indications.
Uses:
Zanubrutinib is classified as a Bruton''s tyrosine kinase inhibitor. Zanubrutinib is a medication for the treatment of adults with mantle cell lymphoma.
Relevant Products
-
ApixabanCAS：503612-47-3
-
D-CamphorCAS：464-49-3
-
Trimeprazine tartrateCAS：4330-99-8
